[2009] [FRI0331] MUCOPHENOLATE MOFETIL IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE
A. Koutroumpas, I. Alexiou, L.I. Sakkas Rheumatology, Thessaly University Medical School. University Hospital of Larissa, Larissa, Greece
Background: T and B cells are activated in systemic sclerosis (SSc) and contribute to its pathogenesis. SSc-associated interstitial lung disease (SSc-ILD) is a major source of morbidity and mortality in patients with SSc.
Objectives: To assess the effect of mofetil mycophenolate (MMF) on lung function and skin in patients with SSc-ILD.
Methods: In this retrospective study we reviewed the medical files of 10 patients with SSc-ILD (8 females, 10 patients with diffuse SSc; mean age, 59.7±12.7 years; disease duration, 7.7±4.7 years). All patients had ground glass opacities on high resolution chest computed tomography. Patients were treated with MMF (2g/day) for 12 months between 2000 and 2008. Lung function tests and the modified Rodnan total skin Score (mRTSS) were assessed at baseline and at 12 months. Results were analyzed by paired Student's t-test.
Results: There was a significant increase in forced vital capacity (FVC) and a non-significant increase in carbon monoxide diffusing capacity (DLCO) at 12 months in patients on MMF (p=0.04 and 0.66, respectively). There was no effect on mRTSS (Table).
Effect of treatment with MMF (2gr/day) on lung function and skin score.| Test | Baseline (mean±SD) | 12 months (mean±SD) | p value |
|---|
| FVC (% predicted) | 79.5±15.7 | 87.1±20.8 | 0.04 | | FEV1 (% predicted) | 81±12.9 | 88.4±18.2 | 0.047 | | DLCO (% predicted) | 80.67±33.5 | 86.67±25.6 | 0.66 | | mRTSS | 17.25±7.8 | 17.7±7.2 | 0.55 |
Disclosure of Interest: None declared
Ann Rheum Dis 2009;68(Suppl3):465
Scleroderma, myositis and related syndromes
|